Abstract 398P
Background
Projections of the national burden of cancer are essential for planning cancer control programs and anticipating future cancer burden on the health service. This study aims to evaluate the current trend and project cancer incidences of the top five cancers in Uganda: Kaposi sarcoma (KS), cervical, breast, prostate, and Non-Hodgkin’s lymphoma (NHL).
Methods
Projections were based on incidence data obtained from the population-based Kampala cancer registry for the 2000-2014 periods, and population data was acquired from the National Bureau of Statistics. Joinpoint software was used to study the trend and presented results using age-specific rates, age-standardized rates, crude rates, and annual percentage change. Two methods were applied to project incidence up to 2029. First, we extrapolated results of the recent trend from joinpoint model to estimate future incidence with the assumption that coefficient estimates will remain constant. Second, we fitted the age-period-cohort model using Nordpred R-package, which accounts for age, period-birth cohort effects, rates were standardized using the standard world population (WHO 2000-2025).
Results
Breast, cervical, and prostate cancer incidences are forecasted to increase by 2029. Their new cases are expected to increase by 200.5%, 98.7% and 184.3 % respectively with the ASRs (per 100,000) escalating from 30.9, 51.9, 44.9 in 2000-2004 to 40.8, 52.7, 64.3 in 2025-2029. Incidences of KS and NHL are, on the other hand, anticipated to decrease for both males and females with both projection methods showing the same results. From 2000 to 2029, the ASR is expected to decrease markedly from 30.3 to 6.1 for KS and from 7.3 to 2.4 for NHL. The reduction in the number of cases is predominantly attributed to the change in their risk. The incidence rates were at peak among people aged from 65 to 74 for breast, cervical, prostate cancers, and those above 75 years for KS and NHL in the observed period. These patterns are expected to remain unchanged in the next decade.
Conclusions
Future research should be directed towards strategies to control the growing burden of breast, cervical, and prostate cancers since their incidence rates are forecasted to increase in the future according to our study.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Asasira Judith.
Funding
“International Cooperation & Education Program (#NCCRI•NCCI 52210-52211, 2019)” of National Cancer Center, Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
437P - Correlation between bio-impedance analysis and abdominal CT scan to diagnose decreased muscle mass in adult cancer patients
Presenter: Andree Kurniawan
Session: Poster display session
Resources:
Abstract
438P - Evaluating mitochondrial biomarkers between fatigue subclasses identified using latent class analysis in early-stage breast cancer patients
Presenter: Yi Long Toh
Session: Poster display session
Resources:
Abstract
440P - Accuracy of risk scoring system to determine delayed chemotherapy induced nausea and vomiting (CINV) in cancer patients
Presenter: Jada Harika
Session: Poster display session
Resources:
Abstract
441P - A pilot cross-sectional study on incidence of liver toxicity in cancer patients on western anti-cancer drug therapy with or without concurrent Chinese herbal medicine
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
442P - Relationship between QOL and support elderly patients with permanent colostomies
Presenter: Yukiko Orii
Session: Poster display session
Resources:
Abstract
443P - The effectiveness of individual nutritional counselling for patients with advanced cancer undergoing chemotherapy: A preliminary study
Presenter: Saori Koshimoto
Session: Poster display session
Resources:
Abstract
444P - The prophylactic effect of 0.1% fluorometholone eye drops on eye disorders caused by high-dose cytarabine
Presenter: Takayuki Tsuchiya
Session: Poster display session
Resources:
Abstract
445P - Safety and feasibility of extending flushing interval every 3 months for maintenance of TICVPS in CRC patients after completion of curative intended treatments
Presenter: Sang Bo Oh
Session: Poster display session
Resources:
Abstract
446P - Accuracy of risk scoring system to determine chemotherapy induced nausea and vomiting (CINV) in cancer patients receiving first cycle chemotherapy
Presenter: Jada Harika
Session: Poster display session
Resources:
Abstract
447P - Hypomagnesaemia: An unnoticed problem in lung cancer patients treated with concurrent chemoradiation
Presenter: Sharif Ahmed
Session: Poster display session
Resources:
Abstract